Maverick Capital Ltd. Increases Stock Position in DaVita Inc. (NYSE:DVA)

Maverick Capital Ltd. raised its position in DaVita Inc. (NYSE:DVA) by 11.5% in the third quarter, Holdings Channel reports. The institutional investor owned 12,886 shares of the company’s stock after purchasing an additional 1,333 shares during the period. Maverick Capital Ltd.’s holdings in DaVita were worth $2,112,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of DVA. Harvard Management Co. Inc. acquired a new stake in DaVita in the 2nd quarter valued at $55,115,000. FMR LLC grew its position in shares of DaVita by 659.9% in the third quarter. FMR LLC now owns 177,406 shares of the company’s stock valued at $29,082,000 after purchasing an additional 154,061 shares during the period. Glenmede Trust Co. NA increased its stake in shares of DaVita by 731.6% during the third quarter. Glenmede Trust Co. NA now owns 123,269 shares of the company’s stock worth $20,207,000 after purchasing an additional 108,446 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in shares of DaVita during the 2nd quarter worth about $9,615,000. Finally, KBC Group NV lifted its stake in DaVita by 27.3% in the 3rd quarter. KBC Group NV now owns 313,519 shares of the company’s stock valued at $51,395,000 after buying an additional 67,250 shares in the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

Wall Street Analysts Forecast Growth

DVA has been the subject of several research reports. Truist Financial boosted their price objective on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research note on Monday, October 7th. UBS Group boosted their price target on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. Bank of America raised their price objective on DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a report on Wednesday, August 7th. Finally, Barclays upped their target price on shares of DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the stock. According to MarketBeat, DaVita presently has a consensus rating of “Hold” and a consensus target price of $161.80.

Insider Activity

In other news, CEO Javier Rodriguez sold 50,000 shares of the company’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $165.05, for a total value of $8,252,500.00. Following the transaction, the chief executive officer now owns 837,835 shares of the company’s stock, valued at $138,284,666.75. This represents a 5.63 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 2.00% of the company’s stock.

DaVita Price Performance

NYSE:DVA opened at $166.17 on Friday. The stock has a 50 day moving average price of $158.57 and a 200 day moving average price of $149.31. The stock has a market cap of $13.63 billion, a PE ratio of 17.93, a P/E/G ratio of 0.94 and a beta of 0.89. The company has a debt-to-equity ratio of 15.78, a quick ratio of 1.33 and a current ratio of 1.37. DaVita Inc. has a one year low of $99.18 and a one year high of $169.51.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing the consensus estimate of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The company had revenue of $3.26 billion for the quarter, compared to analysts’ expectations of $3.25 billion. During the same quarter in the prior year, the firm earned $2.85 EPS. The firm’s revenue was up 4.6% on a year-over-year basis. Equities research analysts expect that DaVita Inc. will post 9.71 EPS for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.